Australia, June 13 -- Regeneron Pharmaceuticals Inc., owns the trademark (2634459) for 'POSAFYVE' till March 11, 2036.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy] and 5 [Pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy;Pharmaceutical preparations for the treatment of auditory and pulmonary diseases and disorders;pharmaceutical preparations for the treatment of obesity]
Type of Mark: Word
Date of Acceptance: March 16
Registration Advertised: June 12
For further details contact PHILLIPS ORMONDE FITZPATRICK.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2634459.
Disclaimer: Curated by HT Syndication.
